MK-5720 + MK-8189 for Schizophrenia

"This research seeks out volunteers who are aged 18 and below 60 years old."

"Our team at Power believes that Panel A can be rated 1 due to the preliminary data collected during Phase 1, which is only indicative of its potential safety and efficacy."

"Affirmative. Information available on clinicaltrials.gov indicates that this medical trial, originally posted in September 15th 2023, is currently accepting applicants. Approximately 64 patients have to be recruited from two separate locations."

"Affirmative. According to clinicaltrials.gov, enrollment for this medical trial is still open and began on September 15th 2023. The last edit was made 6 days later on the 21st of the same month. 64 individuals are required between two sites."

"This research involves 64 individuals diagnosed with schizophrenia that are between 18 and 60. To qualify, participants must meet the DSM-5 criteria for a minimum of two years before their screening appointment, have a history of tolerating antipsychotic medications at regular doses, and not take any medication five days or more (or three half-lives) prior to beginning the intervention."

"This clinical trial, which shall measure results over a 12 month time frame, is aimed at determining the number of participants that experience one or more adverse events during Period 2. Secondary objectives include comparing the area under concentration-time curves (AUC0-28 and AUC0-inf) for MK-8189 in gluteal muscles versus deltoid muscle as well as assessing the maximum concentrations (Cmax) of MK-8189 after administration in both musculature regions."